IPOs often generate significant investor interest, especially in the biopharmaceutical sector where the potential for groundbreaking treatments can lead to substantial long-term value. The pricing range indicates a solid interest level, and the focus on novel drug candidates could attract investors looking for growth opportunities in healthcare. The insider lock-up period ending on November 06, 2024, will also be a critical date for investors to monitor, as it could lead to increased volatility around that time.